Farnesoid X Receptor an Emerging Target to Combat Obesity

Overview

Journal Dig Dis

Specialty Gastroenterology

Date 2017 Mar 2

PMID 28249279

Citations 19

Authors

C Daniel De Magalhaes Filho

Michael Downes

Ronald M Evans

Affiliations

Soon will be listed here.

Abstract

Obesity and its associated diseases, including type 2 diabetes, have reached epidemic levels worldwide. However, available treatment options are limited and ineffective in managing the disease. There is therefore an urgent need for the development of new pharmacological solutions. The bile acid (BA) Farnesoid X receptor (FXR) has recently emerged as an attractive candidate. Initially described for their role in lipid and vitamin absorption from diet, BAs are hormones with powerful effects on whole body lipid and glucose metabolism. In this review, we focus on FXR and how 2 decades of work on this receptor, both in rodents and humans, have led to the development of drug agonists with potential use in humans for treatment of conditions ranging from obesity-associated diseases to BA dysregulation.

Citing Articles

Impact of intestinal microenvironments in obesity and bariatric surgery on shaping macrophages.

Leyderman M, Wilmore J, Shope T, Cooney R, Urao N Immunometabolism (Cobham). 2023; 5(4):e00033.

PMID: 38037591 PMC: 10683977. DOI: 10.1097/IN9.0000000000000033.

Obesity Management in the Primary Prevention of Hepatocellular Carcinoma.

Zunica E, Heintz E, Axelrod C, Kirwan J Cancers (Basel). 2022; 14(16).

PMID: 36011044 PMC: 9406638. DOI: 10.3390/cancers14164051.

Bile acids, bioactive signalling molecules in interoceptive gut-to-brain communication.

Joyce S, OMalley D J Physiol. 2022; 600(11):2565-2578.

PMID: 35413130 PMC: 9325455. DOI: 10.1113/JP281727.

Repurposing FDA-approved drugs as FXR agonists: a structure based in silico pharmacological study.

Jose S, Devi S, Sajeev A, Girisa S, AlQahtani M, Abbas M Biosci Rep. 2022; 43(3).

PMID: 35348180 PMC: 9977715. DOI: 10.1042/BSR20212791.

Bile Acids as a New Type of Steroid Hormones Regulating Nonspecific Energy Expenditure of the Body (Review).

Zagoskin P, Erlykina E Sovrem Tekhnologii Med. 2021; 12(5):114-127.

PMID: 34796012 PMC: 8596256. DOI: 10.17691/stm2020.12.5.13.

References

Adorini L, Pruzanski M, Shapiro D . Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. Drug Discov Today. 2012; 17(17-18):988-97. DOI: 10.1016/j.drudis.2012.05.012. View

Mudaliar S, Henry R, Sanyal A, Morrow L, Marschall H, Kipnes M . Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology. 2013; 145(3):574-82.e1. DOI: 10.1053/j.gastro.2013.05.042. View

Hirschfield G, Mason A, Luketic V, Lindor K, Gordon S, Mayo M . Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology. 2014; 148(4):751-61.e8. DOI: 10.1053/j.gastro.2014.12.005. View

Trivedi P, Hirschfield G, Gershwin M . Obeticholic acid for the treatment of primary biliary cirrhosis. Expert Rev Clin Pharmacol. 2015; 9(1):13-26. DOI: 10.1586/17512433.2015.1092381. View

Makishima M, Okamoto A, REPA J, Tu H, Learned R, Luk A . Identification of a nuclear receptor for bile acids. Science. 1999; 284(5418):1362-5. DOI: 10.1126/science.284.5418.1362. View

Forman B, Goode E, Chen J, Oro A, Bradley D, Perlmann T . Identification of a nuclear receptor that is activated by farnesol metabolites. Cell. 1995; 81(5):687-93. DOI: 10.1016/0092-8674(95)90530-8. View

Wang H, Chen J, HOLLISTER K, Sowers L, Forman B . Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell. 1999; 3(5):543-53. DOI: 10.1016/s1097-2765(00)80348-2. View

Wensveen F, Valentic S, Sestan M, Turk Wensveen T, Polic B . The "Big Bang" in obese fat: Events initiating obesity-induced adipose tissue inflammation. Eur J Immunol. 2015; 45(9):2446-56. DOI: 10.1002/eji.201545502. View

Downes M, Verdecia M, Roecker A, Hughes R, Hogenesch J, Kast-Woelbern H . A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. Mol Cell. 2003; 11(4):1079-92. PMC: 6179153. DOI: 10.1016/s1097-2765(03)00104-7. View

10.

Hwang S, Urizar N, Moore D, Henning S . Bile acids regulate the ontogenic expression of ileal bile acid binding protein in the rat via the farnesoid X receptor. Gastroenterology. 2002; 122(5):1483-92. DOI: 10.1053/gast.2002.32982. View

11.

Prawitt J, Abdelkarim M, Stroeve J, Popescu I, Duez H, Velagapudi V . Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity. Diabetes. 2011; 60(7):1861-71. PMC: 3121443. DOI: 10.2337/db11-0030. View

12.

Kuipers F, Bloks V, Groen A . Beyond intestinal soap--bile acids in metabolic control. Nat Rev Endocrinol. 2014; 10(8):488-98. DOI: 10.1038/nrendo.2014.60. View

13.

Marschall H, Wagner M, Bodin K, Zollner G, Fickert P, Gumhold J . Fxr(-/-) mice adapt to biliary obstruction by enhanced phase I detoxification and renal elimination of bile acids. J Lipid Res. 2005; 47(3):582-92. DOI: 10.1194/jlr.M500427-JLR200. View

14.

Liu Y, Binz J, Numerick M, Dennis S, Luo G, Desai B . Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. J Clin Invest. 2003; 112(11):1678-87. PMC: 281645. DOI: 10.1172/JCI18945. View

15.

Kim I, Ahn S, Inagaki T, Choi M, Ito S, Guo G . Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine. J Lipid Res. 2007; 48(12):2664-72. DOI: 10.1194/jlr.M700330-JLR200. View

16.

Bjursell M, Wedin M, Admyre T, Hermansson M, Bottcher G, Goransson M . Ageing Fxr deficient mice develop increased energy expenditure, improved glucose control and liver damage resembling NASH. PLoS One. 2013; 8(5):e64721. PMC: 3659114. DOI: 10.1371/journal.pone.0064721. View

17.

Alnouti Y . Bile Acid sulfation: a pathway of bile acid elimination and detoxification. Toxicol Sci. 2009; 108(2):225-46. DOI: 10.1093/toxsci/kfn268. View

18.

Potthoff M, Boney-Montoya J, Choi M, He T, Sunny N, Satapati S . FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1α pathway. Cell Metab. 2011; 13(6):729-38. PMC: 3131185. DOI: 10.1016/j.cmet.2011.03.019. View

19.

Gadaleta R, van Erpecum K, Oldenburg B, Willemsen E, Renooij W, Murzilli S . Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut. 2011; 60(4):463-72. DOI: 10.1136/gut.2010.212159. View

20.

Cipriani S, Mencarelli A, Palladino G, Fiorucci S . FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J Lipid Res. 2009; 51(4):771-84. PMC: 2842143. DOI: 10.1194/jlr.M001602. View